501 Fifth Avenue
Eyenovia is a clinical stage, ophthalmic bio-pharmaceutical company which is transforming the way we treat eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia’s breakthrough piezo-dispersion and microdosing technology can enable a portfolio of next-generation, micro-therapeutics for the eye which are designed to significantly reduce ocular and systemic toxicity and greatly improve the risk-benefit profile of both new and existing treatments. At Eyenovia, we believe that when it comes to your eyes, smaller is better.
CEO & President: Sean Ianchulev, MD MPH
Chairman of the Board: Fred Eshelman, PhD
Director, Business Development and Finance: Curt Labelle, MD MBA
Please click here for Eyenovia's science.
Please click here for Eyenovia's pipeline.